Brokerages Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) PT at $51.78
Brokerages Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) PT at $51.78
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has been given an average rating of "Moderate Buy" by the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $52.89.
據MarketBeat報道,BioXcel治療公司(納斯達克代碼:BTAI-GET Rating)目前報道該公司的九位分析師給予該公司“中等買入”的平均評級。一名分析師對該股的評級為持有,六名分析師對該公司的評級為買入。在過去一年更新該股覆蓋範圍的分析師中,平均一年的價格目標是52.89美元。
Several analysts have weighed in on the stock. HC Wainwright dropped their price objective on shares of BioXcel Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a research note on Tuesday, January 3rd. Canaccord Genuity Group boosted their target price on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research report on Friday, November 11th. Mizuho boosted their target price on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research report on Thursday, December 15th. Guggenheim dropped their target price on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, November 11th. Finally, Canaccord Genuity Group boosted their target price on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research report on Friday, November 11th.
幾位分析師對該股進行了分析。1月3日,週二,HC Wainwright將BioXcel治療公司的股票目標價從85.00美元下調至73.00美元,並在一份研究報告中為該公司設定了“買入”評級。Cancord Genuity Group在11月11日星期五的一份研究報告中將BioXcel治療公司的股票目標價從75.00美元上調至76.00美元,並給予該公司“買入”評級。瑞穗在12月15日週四的一份研究報告中將BioXcel治療公司的股票目標價從18.00美元上調至24.00美元。在11月11日星期五的一份研究報告中,古根海姆將BioXcel治療公司的股票目標價從28.00美元下調至25.00美元,併為該公司設定了“買入”評級。最後,Canaccel Genuity Group在11月11日星期五的一份研究報告中將BioXcel治療公司的股票目標價從75.00美元上調至76.00美元,並給予該公司“買入”評級。
Insiders Place Their Bets
內部人士下注
In other BioXcel Therapeutics news, insider Frank Yocca sold 50,000 shares of the business's stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the sale, the insider now directly owns 8,397 shares of the company's stock, valued at approximately $251,910. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Krishnan Nandabalan sold 27,450 shares of the company's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $15.00, for a total value of $411,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Frank Yocca sold 50,000 shares of the company's stock in a transaction on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the insider now directly owns 8,397 shares in the company, valued at $251,910. The disclosure for this sale can be found here. Insiders have sold 133,339 shares of company stock valued at $3,073,310 in the last ninety days. 37.00% of the stock is currently owned by insiders.
在BioXcel治療公司的其他消息中,內部人士Frank Yocca在1月20日星期五的一筆交易中出售了50,000股該公司的股票。這些股票以30.00美元的平均價格出售,總成交額為1500,000.00美元。出售後,這位內部人士現在直接持有該公司8,397股股票,價值約251,910美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在此超鏈接。在其他新聞方面,董事克里希南·南達巴蘭在11月10日(星期四)的一筆交易中出售了27,450股該公司股票。這些股票的平均價格為15.00美元,總價值為411,750.00美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節。此外,內部人士弗蘭克·約卡在1月20日星期五的一次交易中出售了50,000股該公司股票。這些股票以30.00美元的平均價格出售,總成交額為1500,000.00美元。出售完成後,這位內部人士現在直接擁有該公司8,397股,價值251,910美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士賣出了133,339股公司股票,價值3,073,310美元。37.00%的股份目前由內部人士持有。
Institutional Investors Weigh In On BioXcel Therapeutics
機構投資者看好BioXcel治療公司
BioXcel Therapeutics Price Performance
BioXcel治療公司的價格表現
Shares of BioXcel Therapeutics stock opened at $31.66 on Wednesday. BioXcel Therapeutics has a twelve month low of $8.80 and a twelve month high of $32.96. The company has a quick ratio of 10.28, a current ratio of 10.34 and a debt-to-equity ratio of 0.72. The company has a 50-day simple moving average of $22.02 and a two-hundred day simple moving average of $16.54. The stock has a market capitalization of $887.11 million, a price-to-earnings ratio of -6.47 and a beta of 1.16.
BioXcel治療公司的股票週三開盤報31.66美元。BioXcel治療公司的12個月低點為8.80美元,12個月高位為32.96美元。該公司的速動比率為10.28,流動比率為10.34,債務權益比率為0.72。該公司的50日簡單移動均線切入位為22.02美元,200日簡單移動均線切入位為16.54美元。該股市值為8.8711億美元,市盈率為-6.47,貝塔係數為1.16。
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.15). The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.05 million. Analysts forecast that BioXcel Therapeutics will post -5.37 EPS for the current year.
BioXcel治療公司(納斯達克代碼:BTAI-GET Rating)上一次發佈季度收益數據是在11月10日星期四。該公司公佈了本季度每股收益(1.49美元),低於普遍預期的(1.34美元)和(0.15美元)。該業務本季度營收為14萬美元,而分析師預期為305萬美元。分析師預測,BioXcel治療公司本年度的每股收益將達到5.37歐元。
About BioXcel Therapeutics
關於BioXcel治療公司
(Get Rating)
(獲取評級)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
BioXcel治療公司是一家商業階段的生物製藥公司,利用人工智能方法開發神經科學和免疫腫瘤學的變革性藥物。該公司的藥物再創新方法利用現有的批准藥物和/或臨牀驗證的候選產品,以及大數據和專有機器學習算法來識別新的治療指數。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
- 免費獲取StockNews.com關於BioXcel治療(BTAI)的研究報告
- Yext AI搜索平臺能否推動2023年的增長?
- 木薯科學公司的股票以124美元的目標價被低估了?
- 星座品牌:消費者正在降低購買鐵路飲料的價格嗎?
- Capital One股票:次級借款人會破壞漲勢嗎?
- 市場回顧周-1/23-1/27
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受BioXcel治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioXcel治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。